Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Taysha Gene Therapies, Inc. (Nasdaq: TSHA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases, Taysha uses these filings to report on its financial condition, capital-raising activities and material developments in its TSHA-102 Rett syndrome program.
Here, users can review Form 8-K current reports in which Taysha describes material events such as amendments to its at-the-market Sales Agreement for common stock, public follow-on offerings, and key press releases. Recent 8-K filings have incorporated announcements on FDA Breakthrough Therapy designation for TSHA-102, alignment on the REVEAL pivotal trial protocol and statistical analysis plan, and the company’s regaining of full rights to its lead TSHA-102 program.
Investors can also use this page to locate references to quarterly and annual financial results, which are furnished as exhibits to 8-K filings, and to understand how Taysha is funding BLA-enabling manufacturing, REVEAL and ASPIRE clinical trial activities, and general corporate operations. The filings identify TSHA as a Nasdaq-listed issuer with common stock registered under Section 12(b) of the Exchange Act and outline the structure of its equity offering programs.
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the key points of lengthy filings in clear language. Users can quickly see what each 8-K covers, track changes to capital programs and material agreements, and follow how clinical and regulatory milestones for TSHA-102 are reflected in Taysha’s official SEC record. Real-time updates from EDGAR, along with structured views of exhibits and items, help readers navigate the company’s filing history efficiently.
Taysha Gene Therapies insider plans Rule 144 sale of stock. A holder has filed to sell 168,078 shares of Taysha Gene Therapies common stock through broker Maxim Group LLC on or about 01/23/2026, with an indicated aggregate market value of $855,517.02. The filing notes that 273,919,373 shares of common stock were outstanding, providing context for the size of the planned sale. The shares to be sold were acquired on 01/23/2026 via a restricted stock unit (RSU) award from the issuer, which vested and was settled in stock as compensation for the reporting person’s continued service as an employee.
TSHA insider files notice to sell common stock under Rule 144. A Form 144 was filed for the planned sale of 113,824 shares of TSHA common stock through broker Maxim Group LLC on Nasdaq, with an aggregate market value of $579,364.16. The filing notes 273,919,373 shares of TSHA common stock outstanding. The shares to be sold were acquired on 01/23/2026 via an RSU award from the issuer, vesting and settling in stock in exchange for the reporting person’s continued service.
The filer also reported prior TSHA stock sales in the past three months: 110,125 shares of common stock sold on 11/28/2025 for gross proceeds of $522,774.39, and 200,000 shares sold on 01/12/2026 for gross proceeds of $942,738.11. By signing the notice, the person for whose account the securities are to be sold represents that they do not know any undisclosed material adverse information about the issuer’s operations.
A holder of TSHA common stock has filed a notice of proposed sale under Rule 144. The filing covers 30,052 shares of common stock to be sold through Maxim Group LLC on the Nasdaq, with an aggregate market value of $152,964.68. The filing notes that 273,919,373 shares of this class were outstanding at the time of the notice.
The shares to be sold were acquired on 01/23/2026 as a restricted stock unit (RSU) award from the issuer. The RSUs vested and were settled in stock on that date, with the consideration described as the reporting person’s continued service as an employee of the issuer. The signer also represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Taysha Gene Therapies (TSHA) has a planned sale of 54,916 shares of common stock under a Form 144 notice. The shares are to be sold through Maxim Group LLC on the Nasdaq, with an aggregate market value of
The shares come from a restricted stock unit (RSU) award acquired on
An affiliate of the issuer has filed a notice of proposed sale of 32,077 shares of common stock under Rule 144. The planned sale, with an aggregate market value of $163,271.93, is to be executed through Maxim Group LLC on or about 01/23/2026 on the Nasdaq exchange.
The 32,077 shares were acquired on 01/23/2026 via an RSU award from the issuer, with payment in the form of the reporting person’s continued employment and the award vesting and settling in stock on that date. The filing notes that there were 273,919,373 shares of this class of common stock outstanding.
A TSHA security holder filed a notice of proposed sale under Rule 144 to sell 46,064 shares of common stock through broker Maxim Group LLC on or about 01/23/2026 on the Nasdaq market, with an indicated aggregate market value of $234,465.76. The filing notes that there were 273,919,373 shares of this class outstanding at the time of the notice. The seller acquired these shares on 01/23/2026 via a vested RSU award from the issuer, with the consideration described as the reporting person’s continued service as an employee.
An insider of TSHA has filed a notice of proposed sale under Rule 144 to sell up to 100,846 shares of common stock through broker Maxim Group LLC around 01/23/2026 on Nasdaq.
The shares were acquired on the same date via a vested RSU award from the issuer, with consideration described as the reporting person's continued service as an employee. The notice lists an aggregate market value of $513,306.14 for the planned sale and states that 273,919,373 common shares were outstanding.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in Taysha Gene Therapies Inc. BlackRock reports beneficial ownership of 17,852,291 shares of Taysha common stock, representing 6.5% of the class as of 12/31/2025. The firm reports sole power to vote 17,558,530 shares and sole power to dispose of 17,852,291 shares, with no shared voting or dispositive power.
The filing explains that these shares are held across certain BlackRock business units, and that various underlying persons have rights to dividends or sale proceeds, but no single person holds more than five percent of the total outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Taysha Gene Therapies.
Taysha Gene Therapies, Inc. reported that its Chief Financial Officer, Kamran Alam, received new equity awards. On January 12, 2026 he was granted 359,000 shares of common stock in the form of restricted stock units, which will vest in four equal annual installments beginning on January 12, 2027, as long as he remains in continuous service.
On the same date, he also received an employee stock option to buy 231,000 shares of common stock at an exercise price of $4.86 per share, with 25% vesting on January 12, 2027 and the rest vesting in 36 equal monthly installments, subject to continued service. After these awards, he beneficially owned 1,546,603 shares of common stock directly and 231,000 stock options directly.
Taysha Gene Therapies, Inc. reported new equity awards to its Chief Executive Officer, Nolan Sean P. On January 12, 2026, he received 1,008,000 shares of common stock in the form of a restricted stock unit (RSU) award at a price of $0 per share, increasing his directly held common stock to 3,086,358 shares. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on his continued service.
On the same date, he was granted an employee stock option for 648,000 shares of common stock with an exercise price of $4.86 per share, expiring on January 12, 2036. Twenty-five percent of the option vests on January 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter, also subject to continued service. Separately, 1,535,545 shares of common stock are held indirectly through Nolan Capital, LLC, where he has shared voting and investment power.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
